HLN — Haleon plc stock price, charts and financials

QT44Haleon plc

Haleon plc (NYSE: HLN) is a Healthcare company in the Drug Manufacturers - Specialty & Generic industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
9.78
-0.02-0.20%
OverviewShort InterestFilings
HLNQT44Haleon plc·NYSE
9.78-0.20%
TA
Loading chart...
Signal & projected range
Earnings big miss — drift (PEAD)Historical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
TEVA-0.09%$34.43TAK-1.60%$16.56VTRS+0.40%$17.70ELAN-0.47%$25.60RDY+0.25%$12.10LNTH-0.08%$101.11AMRX-1.96%$18.48OCTVV+2.29%$17.40
Snapshot
Index-P/E16.03EPS (ttm)0.61Insider Own-Shs Outstand4.40BPerf Week-4.77%
Market Cap43.07BForward P/E15.92EPS next Y0.61Insider Trans-Shs Float4.43BPerf Month0.62%
Enterprise Value52.85BPEG2.03EPS next Q-Inst Own12.68%Short Float0.29%Perf Quarter5.84%
Income2.72BP/S2.38EPS this Y-8.00%Inst Trans-Short Ratio1.41Perf Half Y-7.39%
Sales18.10BP/B1.94EPS next Y9.43%ROA5.11%Short Interest12.63MPerf YTD-3.26%
Book/sh5.03P/C24.18EPS next 5Y7.88%ROE10.30%52W High11.28 -13.30%Perf Year1.24%
Cash/sh0.40P/FCF27.03EPS past 3/5Y17.12% 9.07%ROIC6.60%52W Low8.65 13.06%Perf 3Y9.40%
Dividend Est.0.13 (1.31%)EV/EBITDA11.47Sales past 3/5Y2.85% 2.79%Gross Margin64.77%Volatility2.10% 1.63%Perf 5Y-
Dividend TTM0.06 (0.61%)EV/Sales2.92EPS Y/Y TTM49.18%Oper. Margin21.87%ATR (14)0.22Perf 10Y-
Dividend Ex-DateAug 14, 2026Quick Ratio0.71Sales Y/Y TTM26.11%Profit Margin15.11%RSI (14)50.05Recom2.25
Dividend Gr. 3/5Y-Current Ratio0.92EPS Q/Q-49.67%SMA20-1.26%Beta-0.06Target Price10.20
Payout36.71%Debt/Eq0.52Sales Q/Q103.02%SMA503.45%Rel Volume0.88Prev Close9.80
Employees24,535LT Debt/Eq0.47EarningsJul 30SMA200-0.07%Avg Volume10.33MPrice9.78
IPO DateJul 25, 2022Option/ShortYes / YesEPS/Sales Surpr.-56.58% -50.36%Net Debt/EBITDA2.59Volume9,144,144Change-0.20%
Analyst Ratings
DateActionAnalystRatingTarget
Jan-23-26UpgradeBarclaysEqual Weight → Overweight
Sep-16-25DowngradeBarclaysOverweight → Equal Weight
Jan-10-25ReiteratedMorgan StanleyOverweight$9.15 → $10
Apr-08-24ReiteratedMorgan Stanley$9.15
Apr-06-23UpgradeArgus ResearchHold → Buy
Latest News
Aug-04-26
Aug-04-2612:41PM
ACCO vs. HLN: Which Stock Is the Better Value Option?zacks.com
Jul-30-26
Jul-30-2607:38AM
Haleon slides as quality of growth questionedproactiveinvestors.com
07:07AM
Haleon plc (HLN) Q2 2026 Earnings Call Transcriptseekingalpha.com
Jul-29-26
Jul-29-2605:39AM
18 Ideal 'Safer' Buyable July Dogs Emerge After 10 Years Of DiggingSeekingAlpha
Jul-28-26
Jul-28-2603:15AM
Bank of New York Mellon Corp Has $25.99 Million Stock Position in Haleon PLC Sponsored ADR $HLNdefenseworld.net
Jul-24-26
Jul-24-2604:07AM
FTSE 100 shares to watch: Lloyds, Barclays, IAG, NatWest, GSK, AstraZenecainvezz.com
Jul-01-26
Jul-01-2612:40PM
LCUT vs. HLN: Which Stock Is the Better Value Option?zacks.com
11:54AM
Haleon Bets on Microsoft AI To Support Growth and Reach One Billion More Consumers by 2030benzinga.com
05:00AM
Haleon to Accelerate AI-powered Transformation With New Five-year Microsoft Collaborationbusinesswire.com
Jun-29-26
Jun-29-2608:30AM
Nasdaq leads Wall Street higher at the open as uneasy Iran truce holdsproactiveinvestors.com
05:51AM
Futura swaps Haleon for Market Performance Group to drive US Eroxon sales - UPDATEproactiveinvestors.com
Jun-26-26
Jun-26-2604:05PM
Unilever exploring $4 billion bid for Thorne supplementsYahoo
Jun-25-26
Jun-25-2612:41PM
Is Haleon plc (HLN) Stock Still a Growth Opportunity After Analyst Downgrade?Yahoo
Jun-15-26
Jun-15-2610:30AM
Haleon: Waiting For A Good Entry Point In Consumer Healthcare LeaderSeekingAlpha
Jun-08-26
Jun-08-2605:15AM
Haleon to Invest £175M in New India Oral Health PlantBenzinga
Company

Haleon plc is a significant global entity in the consumer healthcare sector, engaging in the entire process from scientific research and development to the production and worldwide distribution of various wellness goods. The company's reach extends across North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific region. Its diverse product portfolio encompasses therapeutic solutions for oral care, pain management, respiratory well-being, and digestive health, alongside a comprehensive range of vitamins, minerals, and other dietary supplements. Noteworthy brands within its collection include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. Established in 2021, the company was initially known as DRVW 2022 plc before officially changing its name to Haleon plc in February 2022. It is headquartered in Brentford, United Kingdom.

Ownership
Total institutional ownership12.68%

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
Total Revenue18,10214,56114,35414,05313,38213,12812,69010,819
Cost of Goods Sold Incl. D&A6,3865,0595,4755,3985,2764,9445,1084,693
Gross Profit11,7159,2248,8788,6558,1068,1837,5826,127
Selling, General and Administrative Excl. Other7,1485,7615,5375,3324,9755,2175,4144,588
Research and Development515407381387370353390373
Other Operating Expense26-321141455511360-27221
Operating Income4,0263,1842,8192,4822,2492,2532,0501,144
Interest Expense389439503515428223336
Unusual Expense
————————
Non-Operating Income (Expense)-1029612557173192422
Net Income Before Taxes3,5352,8412,4412,0241,9942,2502,0411,130
Income Taxes793609556643615271526254
Consolidated Net Income2,7212,1521,8431,3041,3061,9121,469836
Net Income From Continuing Operations2,7432,1691,8851,3811,3791,9791,515876
Net Income2,7212,1521,8431,3041,3061,9121,469836
EPS (Recurring)0.610.480.410.300.300.410.310.18
EPS (Basic, Before Extraordinaries)0.610.480.410.300.300.410.310.18
EPS (Diluted)0.610.480.410.300.300.410.310.18
EBITDA4,6063,8013,2122,9232,6903,0412,4521,495
Other After Tax Adjustments
————————
Stock Option Compensation Expense
————————
Price To Earnings Ratio16.0321.2723.3327.5827.05———
Price To Sales Ratio2.403.113.032.712.76———
Gross Margin64.7263.3561.8561.5960.5762.3359.7556.63
Operating Margin22.2421.8719.6417.6616.8117.1616.1510.57
Net Margin15.0314.7812.849.289.7614.5611.587.73
Shares Outstanding4,4504,4814,5664,6324,6184,6174,6174,617
Market Capitalization43,52145,30343,56038,12136,944———
Operating Lease Expense
————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.